In accordance with Regulation G of the Securities and Exchange Commission, the table set forth below reconciles certain financial measures used in this press release that were not calculated in accordance with generally accepted accounting principles, or GAAP, with the most directly comparable financial measure calculated in accordance with GAAP.

 

Three Months Ended
(unaudited)
 
March 31, 2011 March 31, 2010
Operating loss – GAAP $ (1,589 ) $ (5,435 )
Nonrecurring charges (a)   1,053     2,421  

Adjusted operating loss
$ (536 ) $ (3,014 )
 
Net loss – GAAP $ (1,552 ) $ (5,431 )
 
Nonrecurring charges (net of income taxes of $0 and $0, respectively) (a)   1,053     2,421  
Adjusted net loss $ (499 ) $ (3,010 )
 

 
Loss per diluted share – GAAP $ (0.06 ) $ (0.23 )
 
Nonrecurring charges per share (a)   0.04     0.10  
Adjusted loss per diluted share $ (0.02 ) $ (0.13 )
 
(a)   In the first quarter of 2011, we incurred $0.7 million of nonrecurring charges largely related to the integration of our operations with that of Biotel, as well as $0.4 million for the forfeiture and acceleration of certain options. In the first quarter of 2010, we incurred $1.7 million of severance and other exit costs related to the restructuring of our sales and service organizations and management changes, as well as $0.7 million of other charges largely related to our class action and Biotel law suits.
   

Three Months Ended
 
March 31, 2011 March 31, 2010
 
Cash used by operating activities $ (2,240 ) $ (2,952 )
Capital expenditures   (396 )   (1,478 )
Free cash flow   (2,636 )   (4,430 )
 
 

Three Months Ended
 
March 31, 2011 March 31, 2010
 
Operating loss – GAAP $ (1,589 ) $ (5,435 )
Depreciation and amortization expense   3,413     3,197  
EBITDA   1,824     (2,238 )
 

If you liked this article you might like

The BEAT Goes on at BioTelemetry

Buyers Get Picky About Bargains

Shark Bites: Two Big Movers

Shark Bites: Two Big Movers

Ignore Market Jitters, Let Price Action Be the Guide